Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 12/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297955 | 0.85 | RXFP1 (0.44) | QPCTHPGDHIF1AQPCTLRXFP1 | |
| SCHEMBL4293428 | 0.83 | QPCT (0.45) | QPCTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL4296028 | 0.83 | QPCT (0.46) | QPCTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL4299492 | 0.82 | L3MBTL1 (0.37) | QPCTKDM4EALDH1A1TSHRPOLB | |
| SCHEMBL2382575 | 0.80 | QPCT (0.60) | QPCTQPCTL | |
| SCHEMBL4293340 | 0.78 | QPCT (0.52) | QPCTQPCTL | |
| SCHEMBL4293371 | 0.77 | QPCT (0.40) | QPCTQPCTL | |
| SCHEMBL4293538 | 0.77 | QPCT (0.42) | QPCTKDM4EALDH1A1HPGDQPCTL | |
| SCHEMBL4300306 | 0.76 | ALDH1A1 (0.53) | QPCTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL4305666 | 0.76 | QPCT (0.55) | QPCTKDM4EALDH1A1HPGDRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089383-B1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2015-09-16 | — | — | EP | claimed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | claimed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | claimed |
| EP-2089383-B1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2008055945-A1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | QPCT 4/4885KDM4E 2532/4885ALDH1A1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.